HK Stock Movement | JUNSHI BIO (01877) Rises Over 3% in Early Trading as Tuoyi®'s Two New Indications and Junshida® Included in National Reimbursement Drug List

Stock News12-08

JUNSHI BIO (01877) surged over 3% in early trading, reaching HK$24.28 with a turnover of HK$3.177 million by press time. The company announced that two additional indications for its product Toripalimab Injection (brand name: Tuoyi®, product code: JS001) and Angoriximab Injection (brand name: Junshida®, product code: JS002) have been successfully included in the National Reimbursement Drug List (NRDL) for 2025 under Category B. The updated NRDL will take effect on January 1, 2026.

As of the announcement date, all four of the company’s commercialized products—Tuoyi®, Adalimumab Injection (brand name: Junmaikang®, product code: UBP1211), Deuremidevir Hydrobromide Tablets (brand name: Mindewei®, product code: VV116/JT001), and Junshida®—have been included in the NRDL.

Tuoyi® now covers all 12 approved indications in mainland China, making it the only anti-PD-1 monoclonal antibody in the NRDL for treating renal cell carcinoma, triple-negative breast cancer, and melanoma. Junshida®, included for the first time, is the only domestically developed PCSK9-targeted drug in the updated NRDL for statin-intolerant patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185043125?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185043125","market":"sh","top_or_hot":-1,"title":"HK Stock Movement | JUNSHI BIO (01877) Rises Over 3% in Early Trading as Tuoyi®'s Two New Indications and Junshida® Included in National Reimbursement Drug List","media":"Stock News","content":"<p>JUNSHI BIO (01877) surged over 3% in early trading, reaching HK$24.28 with a turnover of HK$3.177 million by press time. The company announced that two additional indications for its product Toripalimab Injection (brand name: Tuoyi®, product code: JS001) and Angoriximab Injection (brand name: Junshida®, product code: JS002) have been successfully included in the National Reimbursement Drug List (NRDL) for 2025 under Category B. The updated NRDL will take effect on January 1, 2026.</p>\n<p>As of the announcement date, all four of the company’s commercialized products—Tuoyi®, Adalimumab Injection (brand name: Junmaikang®, product code: UBP1211), Deuremidevir Hydrobromide Tablets (brand name: Mindewei®, product code: VV116/JT001), and Junshida®—have been included in the NRDL.</p>\n<p>Tuoyi® now covers all 12 approved indications in mainland China, making it the only anti-PD-1 monoclonal antibody in the NRDL for treating renal cell carcinoma, triple-negative breast cancer, and melanoma. Junshida®, included for the first time, is the only domestically developed PCSK9-targeted drug in the updated NRDL for statin-intolerant patients.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | JUNSHI BIO (01877) Rises Over 3% in Early Trading as Tuoyi®'s Two New Indications and Junshida® Included in National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | JUNSHI BIO (01877) Rises Over 3% in Early Trading as Tuoyi®'s Two New Indications and Junshida® Included in National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JUNSHI BIO (01877) surged over 3% in early trading, reaching HK$24.28 with a turnover of HK$3.177 million by press time. The company announced that two additional indications for its product Toripalimab Injection (brand name: Tuoyi®, product code: JS001) and Angoriximab Injection (brand name: Junshida®, product code: JS002) have been successfully included in the National Reimbursement Drug List (NRDL) for 2025 under Category B. The updated NRDL will take effect on January 1, 2026.</p>\n<p>As of the announcement date, all four of the company’s commercialized products—Tuoyi®, Adalimumab Injection (brand name: Junmaikang®, product code: UBP1211), Deuremidevir Hydrobromide Tablets (brand name: Mindewei®, product code: VV116/JT001), and Junshida®—have been included in the NRDL.</p>\n<p>Tuoyi® now covers all 12 approved indications in mainland China, making it the only anti-PD-1 monoclonal antibody in the NRDL for treating renal cell carcinoma, triple-negative breast cancer, and melanoma. Junshida®, included for the first time, is the only domestically developed PCSK9-targeted drug in the updated NRDL for statin-intolerant patients.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1185043125","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185043125","pubTimestamp":1765157897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JUNSHI BIO (01877) surged over 3% in early trading, reaching HK$24.28 with a turnover of HK$3.177 million by press time. The company announced that two additional indications for its product...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","BK1583":"高瓴概念","BK0239":"医药制造","01877":"君实生物","BK1515":"抗疫概念","BK1161":"生物科技"},"translate_title":"港股动向|君实生物(01877)早盘涨超3%领涨拓益®的两个新适应症和君仕达®纳入国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1,"01877":1},"content_text":"JUNSHI BIO (01877) surged over 3% in early trading, reaching HK$24.28 with a turnover of HK$3.177 million by press time. The company announced that two additional indications for its product Toripalimab Injection (brand name: Tuoyi®, product code: JS001) and Angoriximab Injection (brand name: Junshida®, product code: JS002) have been successfully included in the National Reimbursement Drug List (NRDL) for 2025 under Category B. The updated NRDL will take effect on January 1, 2026.\nAs of the announcement date, all four of the company’s commercialized products—Tuoyi®, Adalimumab Injection (brand name: Junmaikang®, product code: UBP1211), Deuremidevir Hydrobromide Tablets (brand name: Mindewei®, product code: VV116/JT001), and Junshida®—have been included in the NRDL.\nTuoyi® now covers all 12 approved indications in mainland China, making it the only anti-PD-1 monoclonal antibody in the NRDL for treating renal cell carcinoma, triple-negative breast cancer, and melanoma. Junshida®, included for the first time, is the only domestically developed PCSK9-targeted drug in the updated NRDL for statin-intolerant patients.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185043125","isCrawlerRequest":true}